Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perindopril/amlodipine - Servier

Drug Profile

Perindopril/amlodipine - Servier

Alternative Names: Acerycal; Amlodipine/perindopril; Bi-Prestarium; Calcertil; Co-Prestarium; Coveram; Covercard; Covercor; Coverlam; Coversical; Coversyl AM; Perindopril arginine/amlodipine besylate; Prestalia; Prestance; Prestarium-Co; Presteram; Prexanor; Proacertil; Procoversyl; Reaptan; S-05985; Viacoram

Latest Information Update: 05 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Servier
  • Developer Servier; Symplmed
  • Class Antihypertensives; Dihydropyridines; Indoles
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery disease; Hypertension

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 05 Dec 2017 Chemical structure information added
  • 06 Jun 2017 Marina Biotech acquires Prestalia® (perindopril/amlodipine) from Symplmed Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top